Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ITRM

Iterum Therapeutics Plc

Sep 27 • 04:00PM ET

1.05

Dollar change +0.01
Percentage change 0.96	%

Healthcare • Biotechnology • Ireland • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.00	Insider Own	3.33%	Shs Outstand	22.71M	Perf Week	0.00%
Market Cap	23.96M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	21.95M	Perf Month	-5.80%
Income	-28.34M	PEG	-	EPS next Q	-0.17	Inst Own	1.47%	Short Float	1.56%	Perf Quarter	-12.08%
Sales	0.00M	P/S	-	EPS this Y	67.16%	Inst Trans	-9.03%	Short Ratio	1.08	Perf Half Y	-33.65%
Book/sh	-0.66	P/B	-	EPS next Y	50.00%	ROA	-86.93%	Short Interest	0.34M	Perf Year	55.15%
Cash/sh	0.52	P/C	2.04	EPS next 5Y	-	ROE	-555.68%	52W Range	0.62 - 2.50	Perf YTD	-46.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.62%	ROI	-	52W High	-57.80%	Beta	2.25
Dividend TTM	-	Quick Ratio	0.77	Sales past 5Y	-39.15%	Gross Margin	-	52W Low	69.61%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.77	EPS Y/Y TTM	55.81%	Oper. Margin	0.00%	RSI (14)	44.71	Volatility	7.23% 9.47%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	68.08%	Payout	-	Rel Volume	0.70	Prev Close	1.04
Sales Surprise	-	EPS Surprise	48.89%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	317.14K	Price	1.05
SMA20	-2.68%	SMA50	-9.06%	SMA200	-27.05%	Trades		Volume	223,575	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy	$2.50
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$7 → $2
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy	$17

Sep-24-24 10:33AM	Iterums oral sulopenem acceptance hinges on antibiotic stewardship efforts (Pharmaceutical Technology)
Sep-10-24 07:00AM	Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women (GlobeNewswire) -12.04%
Sep-06-24 04:30PM	Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 08:09AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-14-24 07:00AM	Iterum Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:18AM	Loading…
Aug-10-24 08:18AM	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-07-24 04:30PM	Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Aug-06-24 05:30PM	Iterum Therapeutics Announces Expiration and Results of Rights Offering (GlobeNewswire)
Aug-02-24 08:00AM	Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem (GlobeNewswire)
Jul-22-24 07:30AM	Iterum Therapeutics Commences Rights Offering (GlobeNewswire)
Jun-21-24 08:00AM	Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections (GlobeNewswire) +7.83%
Jun-05-24 08:00AM	Iterum Therapeutics to Present Data at ASM Microbe 2024 (GlobeNewswire)
May-31-24 08:00AM	Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections (GlobeNewswire) +16.28%
May-14-24 08:21AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 10:49PM	Q1 2024 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
11:53AM	Loading…
11:53AM	ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Iterum Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:00AM	Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-29-24 08:00AM	Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem (GlobeNewswire) -7.78%
Apr-02-24 10:22AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 12:09AM	Q4 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-21-24 04:30PM	Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 (GlobeNewswire)
Mar-15-24 08:00AM	Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat (GlobeNewswire)
Mar-07-24 07:57AM	Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up (Zacks)
Mar-06-24 08:00AM	Iterum Therapeutics Provides Business Update (GlobeNewswire) +17.79%
Feb-01-24 03:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC (GuruFocus.com)
Jan-30-24 07:00AM	Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (PR Newswire) -11.73%
Dec-04-23 08:00AM	Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule (GlobeNewswire)
12:22PM	Loading…
Nov-15-23 12:22PM	Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.76%
12:08AM	Q3 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:00AM	Iterum Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 08:30AM	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (GlobeNewswire) +6.87%
Oct-12-23 09:15AM	Iterum Therapeutics to Present Data at IDWeek 2023 (GlobeNewswire)
Aug-11-23 10:10PM	Q2 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents) +7.92% -9.17%
07:00AM	Iterum Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 05:00PM	Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 (GlobeNewswire)
Jun-27-23 09:50AM	Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% (Zacks)
Jun-21-23 08:35AM	Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera (Zacks)
Jun-12-23 06:23PM	Iterum Therapeutics to Present Data at ASM Microbe 2023 (GlobeNewswire)
May-12-23 07:00AM	Iterum Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
Apr-20-23 05:00PM	Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials (GlobeNewswire) -5.04% -5.31%
Apr-13-23 12:00PM	All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy (Zacks) +8.27%
Mar-18-23 02:06AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:16PM	Q4 2022 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents) +15.00% -6.09%
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 05:00PM	Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 (GlobeNewswire) -8.70% -8.57%
Jan-11-23 06:00PM	Iterum Therapeutics Reports Employment Inducement Grant (GlobeNewswire) +12.50%
Dec-15-22 08:00AM	Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem (GlobeNewswire) +6.14%
Nov-10-22 07:00AM	Iterum Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-20-22 07:30AM	Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (GlobeNewswire) -5.56%
Oct-17-22 05:19PM	Iterum Therapeutics to Present Data at IDWeek 2022 (GlobeNewswire) +6.06%
Sep-19-22 07:30AM	Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem (GlobeNewswire)
Sep-07-22 09:15AM	Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +7.98%
Sep-01-22 04:15PM	Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule (GlobeNewswire) -6.51%
Aug-17-22 09:45AM	Iterum Therapeutics (NASDAQ:ITRM) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) -19.24%
Aug-16-22 09:00PM	Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split (GlobeNewswire)
Aug-12-22 07:00AM	Iterum Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-11-22 02:31PM	Iterum Therapeutics Shares Are Surging - Read Why (Benzinga) +40.42%
07:30AM	Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA (GlobeNewswire)
Jul-06-22 04:30PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-14-22 05:00PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-22 07:00AM	Iterum Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +7.84%
May-11-22 08:00AM	Iterum Therapeutics Provides Regulatory Update (GlobeNewswire) -11.37%
Apr-25-22 05:06PM	Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (GlobeNewswire) -6.69%
Mar-28-22 10:19AM	Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22 (Benzinga) -14.27%
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 08:00AM	Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 (GlobeNewswire)
Mar-10-22 08:00AM	Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (GlobeNewswire)
Feb-08-22 05:00PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
Dec-14-21 04:30PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.63%
07:12AM	Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load? (Simply Wall St.)
Dec-13-21 08:00AM	Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer (GlobeNewswire)
Nov-22-21 10:00AM	Iterum Therapeutics PLC (ITRM) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.07%
Nov-12-21 07:00AM	Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -6.73%
Nov-05-21 07:00AM	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021 (GlobeNewswire)
Oct-04-21 02:58PM	ITRM LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Iterum Therapeutics Plc (Newsfile) -6.74%
01:28PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Iterum Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
12:33PM	ITRM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Iterum Therapeutics Plc Limited Shareholders (Newsfile)
11:05AM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc and Encourages Investors to Contact the Firm (GlobeNewswire)
10:45AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ITRM, SESN and WDH (ACCESSWIRE)
10:00AM	Last Few Hours for Investors to Actively Participate in Iterum Therapeutics plc (ITRM) Class Action - Bronstein, Gewirtz & Grossman, LLC (Newsfile)
09:40AM	CLASS ACTION UPDATE for ZY, ITRM and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
08:36AM	ITRM Final Deadline Today: Rosen, National Trial Lawyers, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - ITRM (Newsfile)
07:30AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Iterum Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
05:34AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 - ITRM (Newsfile)
Oct-03-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Iterum Therapeutics plc of Class Action Lawsuit and Upcoming Deadline ITRM (GlobeNewswire)
10:20AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATVI, ITRM and KPLT (ACCESSWIRE)
10:00AM	FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action ITRM (GlobeNewswire)
Oct-01-21 07:00PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc and Encourages Investors to Contact the Firm (Business Wire) +7.65% -6.74%
03:45PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ITRM, ATIP and SESN (ACCESSWIRE)
03:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Iterum Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - ITRM (Newsfile)
11:30AM	CLASS ACTION UPDATE for ITRM, SLQT and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	Monday Deadline for Investors to Actively Participate in Iterum Therapeutics plc (ITRM) Class Action - Bronstein, Gewirtz & Grossman, LLC (Business Wire)
09:13AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Iterum Therapeutics Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 4, 2021 - ITRM (Newsfile)
07:45AM	DEADLINE MONDAY REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Iterum Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dunne Michael W.	Director	Dec 22 '23	Buy	1.40	25,000	35,000	113,754	Dec 27 09:00 AM
Dunne Michael W.	Director	Dec 18 '23	Buy	1.84	10,000	18,442	88,754	Dec 19 04:15 PM
Dunne Michael W.	Director	Nov 22 '23	Buy	2.03	20,000	40,690	78,754	Nov 27 05:00 PM
Fishman Corey N.	Chief Executive Officer	Nov 20 '23	Buy	1.59	10,000	15,863	54,449	Nov 20 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ITRM

Iterum Therapeutics Plc

Upgrade your FINVIZ experience